Please login to the form below

Not currently logged in
Email:
Password:

BMS’ Dr Mike Burgees joins Turnstone Biologics

He joins the immuno-oncology group as its president of R&D

Turnstone Biologics, a North American clinical-stage immuno-oncology company, has appointed Dr Mike Burgees as its president of research and development, a role that will see him lead all functions in the R&D organisation, including preclinical and clinical development.

Dr Burgees has over 20 years’ experience in drug development, most recently as senior vice president, cardiovascular, fibrosis and immunoscience at Bristol-Myers Squibb (BMS).

He said: “Turnstone Biologics is uniquely positioned to deliver breakthrough viral-based immunotherapies for patients with cancer.

“I look forward to working closely with Turnstone’s experienced team and founders, who are driven by science and innovation, to bring these breakthrough medicines to patients.”

Prior to his time at BMS, Dr Burgees held several senior leadership positions at Roche, including acting global head of Roche Pharma Research and Early Development (pRED) and senior vice president and global head of oncology research and early development.

Sammy Farah, president and chief executive officer, Turnstone Biologics, said: “Mike is one of the most respected research and development leaders in the pharmaceutical industry, and has successfully led the global development and registration of several anti-cancer medicines.

“Mike’s oncology expertise will be instrumental in advancing the development of our next-generation viral immunotherapies and powerful immuno-oncology R&D capabilities.”

6th December 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics